Brought to you by 
Arrowhead Research acquires targeted drug delivery company Alvos Therapeutics
09 Nov 2020
Executive Summary
Arrowhead Research Corp. (nanomedicines for cancer, obesity, and related metabolic and liver disorders) has acquired privately owned cancer drug discovery company Alvos Therapeutics Inc. (formerly Mercator Therapeutics). Arrowhead issued 315k of its common shares up front (valued at about $2mm) and could issue another $23.5mm in stock earn-outs based on clinical and regulatory achievements, plus additional sales-based earn-outs for the first three drugs developed.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arrowhead Research acquires targeted drug delivery company Alvos Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice